bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract A089: Role of Vardhamana Pippali Rasayana (VPR) in human breast cancer cells
Authors: Tripathi Dr.Richa , Singh Shivam , Gupta Subhash , Huddar VG , Nesari Tanuja M , Sharma Ashok 
Published: February 2024

Abstract
Serious concerns include delayed diagnosis and adverse side-effects of conventional treatment leading to residual morbidity in Breast cancer (BC) globally. Traditional Indian medicines/herbs via combination of conventional cancer are gaining increasing acceptance worldwide, playing a pivotal role as proven by their efficacy evaluation studies. Many plants are known to reduce the cell proliferation and tumor development after their treatment. Vardhamana Pippali Rasayana (VPR), an Ayurvedic herbal preparation of pippali (Piper longum) in gradually increasing and tapering dose is used to treat many cancers without any adverse side-effects. However, its anti-cancer role in breast cancer is not known yet. The present study has explored the cytotoxic and apoptotic effects of VPR in triplicates on human breast cancer (MCF7) and normal breast epithelial (MCF10A) cell lines at different concentrations after extracting piperine in aqueous and hydro-alcoholic soxhlet extract (0.25 to 50 μg/μl). The cytotoxic activity was carried out by MTT assay and results showed that a low IC50 was observed at 3.75 μg/μl of VPR against MCF-7 as compared with normal breast epithelial cells. Detection of apoptotic cells using suitable Annexin V was done and there was a time-dependent increase in percentage of annexin V positive cells upon treatment. The above results indicate that VPR may have a strong anti-cancerous potential. But other functional assays are warranted to validate the efficacy of the drug against breast cancer which are under progress in our laboratory.
Citation Format: Dr.Richa Tripathi, Shivam Singh, Subhash Gupta, VG Huddar, Tanuja M Nesari, Ashok Sharma. Role of Vardhamana Pippali Rasayana (VPR) in human breast cancer cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr A089.
Abstract B029: Combinations of metformin and BH3-mimetic drugs synergistically induce immunogenic cell death in breast cancer cells
Authors: Savelius Mariel , Id Linda , Anttila Johanna , Liu Ruixian , Suleymanova Ilida , Saarela Jani , Klefström Juha 
Published: February 2024

Abstract
There is a compelling medical need for novel and safe treatment options for patients with advanced and difficult to treat breast cancer. Our previous findings have demonstrated that a combination of metformin and navitoclax (BCL-2/BCL-XL inhibitor) successfully prevents tumor growth in patient derived xenograft and syngrafted mouse models of aggressive MYC-driven breast cancer. This outcome is due to the synthetic lethal action of these drugs in tumors with elevated MYC expression. Here, we explored the combinations of metformin with all clinically applicable anti-apoptotic BCL-2 family protein inhibitors (BH3-mimetics) in a panel of 15 triple-negative breast cancer cell lines with distinct endogenous MYC levels, as well as inducible MYC models. We used cytotoxicity assays and analyzed the data with SynergyFinder, an interactive analysis and visualization tool, to calculate the degree of combination synergy utilizing Zero interaction potency reference model. Through these cytotoxicity assays, we defined which metformin and BH3-mimetic drug combination induces most synergistic cell death in a MYC-synthetic lethal manner. Additionally, we used DAMP reporter cell lines and peripheral blood mononuclear cell-based dendritic cell activation assays to evaluate the immunogenic potential of combination-induced cell death. We show that targeting MCL-1 or BCL-2/XL with BH3-mimetics MIK-665 and navitoclax, respectively, and combining them with metformin, induces synergistic cell death in MYC-high cancer cells. We also show that cell death caused by these drug combinations promotes maturation of dendritic cells. In conclusion, targeting MYC-high tumors with synthetic lethal strategies, including BH3-mimetics and metformin, may offer new opportunities to combine with immunotherapies for the treatment of breast cancer.
Citation Format: Mariel Savelius, Linda Id, Johanna Anttila, Ruixian Liu, Ilida Suleymanova, Jani Saarela, Juha Klefström. Combinations of metformin and BH3-mimetic drugs synergistically induce immunogenic cell death in breast cancer cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr B029.
Abstract B033: Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis
Authors: Mukherjee Debarati , Previs Rebecca A , Haines Corinne N , Abo Muthana Al , Juras Patrick K , Strickland Kyle C , Chakraborty Binita , Whitaker Regina , Patierno Steven R , Freedman Jennifer A , Chang Ching-Yi , McDonnell Donald P 
Published: February 2024

Abstract
Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains high, and long-term survival outcomes remain poor. In a search for new therapeutic targets for this disease, we observed that elevated expression of the serine/threonine kinase calcium/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) is highly correlated with tumor invasiveness. In validation studies, genetic disruption of CaMKK2 expression or inhibition of its activity with small molecule inhibitors disrupted spontaneous metastatic outgrowth from primary tumors in murine xenograft models of TNBC. High-grade serous ovarian cancer (HGSOC), a high-risk, poor prognosis ovarian cancer subtype, shares many features with TNBC, and CaMKK2 inhibition effectively blocked metastatic progression in a validated xenograft model of this disease. Mechanistically, CaMKK2 increased the expression of the phosphodiesterase PDE1A which hydrolyzed cyclic guanosine monophosphate (cGMP) to decrease the cGMP-dependent activity of protein kinase G1 (PKG1). Inhibition of PKG1 resulted in decreased phosphorylation of vasodilator stimulated phosphoprotein (VASP), which in its hypophosphorylated state binds to and regulates F-actin assembly to facilitate cell movement. Together, these findings establish a targetable CaMKK2-PDE1A-PKG1-VASP signaling pathway that controls cancer cell motility and metastasis by impacting the actin cytoskeleton. Further, it identifies CaMKK2 as a potential therapeutic target that can be exploited to restrict tumor invasiveness in patients diagnosed with early-stage TNBC or localized HGSOC.
Citation Format: Debarati Mukherjee, Rebecca A Previs, Corinne N Haines, Muthana Al Abo, Patrick K Juras, Kyle C Strickland, Binita Chakraborty, Regina Whitaker, Steven R Patierno, Jennifer A Freedman, Ching-Yi Chang, Donald P McDonnell. Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr B033.
Abstract IA23: "NO Target for Cancer Stem Cells"
Authors: Chang Jenny C. 
Published: February 2024

Abstract
Developing novel therapies that target cancer metastasis, chemoresistant cancer stem cells, and augment the efficacy of systemic chemo/radiotherapies is crucial to reducing cancer-associated mortality. A protein within the tumor microenvironment that has gained interest as a promising therapeutic target is nitric oxide synthase (NOS). Our previous findings have shown that increased inducible nitric oxide synthase (iNOS) expression is a poor prognostic indicator and associated with worse overall survival in triple negative breast cancer (TNBC) patients. Nitric oxide (NO) is a unique molecule in its ability to target multiple oncogenic pathways in a spatial and temporal manner, such as PI3K, extracellular signal-regulated kinase (ERK), β-catenin pathway, transforming growth factor beta (TGFβ) signaling, and hypoxia-inducible factor (HIF). Growing evidence has also suggested that hyperactivation of the phosphoinositide-3-kinase (PI3K) survival signaling pathway may be one of the most common oncogenic aberrations in certain TNBC subsets, in particular metaplastic breast cancer (MpBC). We will summarize the role of NO in PI3K-Akt pathway activation in human TNBC, as well as data from The Cancer Genome Atlas of the role of iNOS and PI3K-Akt interaction. This review discusses the current knowledge of the roles of nitric oxide (NO) in tumor progression and cancer metastasis, and promising preclinical studies that evaluated NOS inhibitors as an anti-cancer therapy. Lastly, we will offer a perspective on utilizing NOS inhibitors in the clinical setting, highlighting the prospects and outstanding challenges.
Citation Format: Jenny C. Chang. "NO Target for Cancer Stem Cells" [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr IA23.
Abstract PR02: Modeling breast cancer through somatic precision gene editing with high flexibility and efficiency
Authors: Bu Wen , Li Yi , Creighton Chad J , Heavener Kelsey S , Gutierrez Carolina , Dou Yongchao , Jiang Weiyu , Zhang Bing , Ku Amy T , Huang Shixia 
Published: February 2024

Abstract
CRISPR/Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR/Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in both normal and hyperplastic mammary glands led to swift tumorigenesis. The resulting tumors shared some histological, transcriptome, and proteome features with tumors induced by lentivirus-mediated expression of the respective oncogenes, but they also exhibited some distinct characteristics, particularly showing less inter-tumor variation, thus potentially offering more consistent models for cancer studies and therapeutic development. Therefore, this technological advance fills a critical gap between the power of CRISPR technology and high-fidelity mouse models for studying human tumor evolution and preclinical drug testing.
Citation Format: Wen Bu, Yi Li, Chad J Creighton, Kelsey S Heavener, Carolina Gutierrez, Yongchao Dou, Weiyu Jiang, Bing Zhang, Amy T Ku, Shixia Huang. Modeling breast cancer through somatic precision gene editing with high flexibility and efficiency [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr PR02.
Abstract PR09: Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene
Authors: Huang Huaizhi (Gilbert) , Hu Chunling , Na Jie , Abozaid Mohamed , Munankarmy Amik , Rao Tara , Lumby Carolyn A. Dunn , Lyra Paulo Cilas Morais , Couch Ronan E. , Persons Benjamin R. , Polley Eric C. , Karam Rachid , Pesaran Tina , Yadav Siddhartha , Monteiro Alvaro N.A. , Boddicker Nicholas J. , Domchek Susan M. , Richardson Marcy E. , Couch Fergus J. 
Published: February 2024

Abstract
Many germline BRCA2 missense variants of uncertain significance (VUS) remain to be clinically classified as pathogenic or benign. Here we identify 70 missense VUS in the DNA binding domain (DBD) of BRCA2 that partially reduced homologous recombination DNA repair activity of the protein in a homology directed DNA repair cell-based assay. CRISPR/cas9-based knockin of these variants reduced cell survival of haploid cells and conferred increased sensitivity to the PARP inhibitor Olaparib. Sequence alignment analysis found that the variants were highly conserved across species from pufferfish to human. Structural analysis showed that these variants are located predominantly in unstructured regions of the DBD. Case-control association studies showed that the hypomorphic variants conferred moderate risks of breast (OR:2.85; 95%CI:1.43-5.88) and ovarian cancer (OR:3.37; 95%CI:1.30-8.54) that were significantly different from risks associated with known pathogenic and benign variants. Cumulative lifetime risks of breast and ovarian cancer among carriers were estimated at 25% and 4.7%, respectively. Age at diagnosis of breast cancer among hypomorphs carriers was 55 years of age as opposed to 48 years of age for carriers of pathogenic variants. In addition, the combination of functional and other genetic data in an ACMG/AMP-like variant classification model reclassified 39 variants as likely pathogenic. This novel group of low penetrance missense variants further calibrate BRCA2 variant classification methods and have significant implications for the management of variant carriers.
Citation Format: Huaizhi (Gilbert) Huang, Chunling Hu, Jie Na, Mohamed Abozaid, Amik Munankarmy, Tara Rao, Carolyn A. Dunn Lumby, Paulo Cilas Morais Lyra, Ronan E. Couch, Benjamin R. Persons, Eric C. Polley, Rachid Karam, Tina Pesaran, Siddhartha Yadav, Alvaro N.A. Monteiro, Nicholas J. Boddicker, Susan M. Domchek, Marcy E. Richardson, Fergus J. Couch. Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr PR09.
Abstract A001: Genomic signatures of past and present chromosomal instability in Barrett’s esophagus and early esophageal adenocarcinoma
Authors: Bao Chunyang 
Published: February 2024

Abstract
Abstract: The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution indicating multigenerational chromosomal instability that is initiated by cell division errors but propagated only after p53 loss. While abnormal mitosis, including whole-genome duplication, underlies chromosomal copy-number changes, segmental alterations display signatures of successive breakage-fusion-bridge cycles and chromothripsis of unstable dicentric chromosomes. Our analysis elucidates how multigenerational chromosomal instability generates copy-number variation in BE cells, precipitates complex alterations including DNA amplifications, and promotes their independent clonal expansion and transformation. In particular, we suggest sloping copy-number variation as a signature of ongoing chromosomal instability that precedes copy-number complexity. These findings suggest copy-number heterogeneity in advanced cancers originates from chromosomal instability in precancerous cells and such instability may be identified from the presence of sloping copy-number variation in bulk sequencing data.
Citation Format: Chunyang Bao. Genomic signatures of past and present chromosomal instability in Barrett’s esophagus and early esophageal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2):Abstract nr A001.
Abstract A017: Computational and mouse models of adaptive therapy with multiple drugs in breast cancer
Authors: Maley Carlo C. , Seyedi Sareh , Saha Daniel , Anderson Alexander 
Published: February 2024

Abstract
Adaptive therapy is an evolutionary approach to cancer therapy designed to maintain control of therapeutically resistant cells and thereby extend both time to progression and patient survival. Most of the previous work in adaptive therapy has used a single cytotoxic drug, and yet there are still many variations of adaptive therapy protocols. Although multidrug therapy is standard for most cancers, there is a combinatorial explosion of possible protocols with an increase in the number of drugs used. We set out to explore which protocols are likely to work best, under which conditions, using computational models. We explored 2 drug therapies but allowed the drugs to be cytotoxic or cytostatic. We tested the effects of varying the fitness cost of resistance, the amount of turnover in the tumors, and the ability of cells to replace their neighbors under crowded conditions. Adaptive therapy tends to work best when there is more competition between cells in the cancers. We also explored different dosing schedules with both fixed doses and with varying the doses as a function of tumor burden dynamics. We also selected ER+ breast cancer (MCF7) cells to be resistant to both fulvestrant (an anti-estrogen therapy) and palbociclib (a CDK4/6 targeted therapy). These endocrine-resistant ER+ breast cancer cells represent the target population for a clinical trial in endocrine-resistant ER+ metastatic breast cancer that we are seeking to open at the Mayo Clinic. We tested a few of the adaptive therapy protocols with those cells in immune-compromised mice, using either gemcitabine, capecitabine or both drugs. In general, our computational models suggest that the less drug that a protocol uses, the longer we are able to keep control over the cancers. This was corroborated in our mouse experiments. However, if too little drug is used it can’t even control the sensitive cells in the tumors, leading to a sort of Goldilocks effect for the dosing. Capping the maximum dose at a relatively low level, and modulating the dose below that level, led to long-term control for many of the protocols. Many of the tumors in the mice remained dormant for many weeks after we stopped adaptive therapy, for unknown reasons. Our results support adaptive therapy as a promising approach for both extending time to progression and improving quality of life by reducing toxicity. We are using these results to design our clinical trial.
Citation Format: Carlo C. Maley, Sareh Seyedi, Daniel Saha, Alexander Anderson. Computational and mouse models of adaptive therapy with multiple drugs in breast cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2):Abstract nr A017.
Abstract B036: Mutational landscape and genetic feature of gastric adenocarcinoma in multiple Chinese ethnicities
Authors: Zong Liang 
Published: February 2024

Abstract
Gastric cancer is a heterogeneous malignancy and the fifth most common cancer worldwide, with 44% of cases occurring in China. Elucidation of genetic subtypes may improve gastric cancer treatment planning. Matched tumour and peritumoural (non-malignant gastric mucosa) tissue samples were collected from 306 Chinese patients and subjected to whole-exome sequencing (WES). The results were used to produce a Chinese Gastric Cancer Genome Atlas (CGCGA). Patients from nine Chinese ethnic groups (Han, Zhuang, Hui, Uygur, Yi, Tibetan, Mongolian, Bai, and Kazakh), representing 95% of the Chinese population were included. Systematic comparison of CGCGA data with TCGA (The Cancer Genome Atlas) data, in which 437 gastric cancer cases are represented, showed that genomic alteration signatures in the present cohort differed markedly from those reported for Western cohorts. TP53 and FAT1 deletions were more frequent (35% vs. 0%) while ARID1A deletions (13% vs. 25%), MYC oncogene amplifications (53% vs. 70%), and SMAD4 deletions (34% vs. 46%) were less frequent in our CGCGA data than in the TCGA data. TRIM49B mutation was associated with worse survival. Thus, TRIM49B was identified as a novel oncogene. The Zhuang ethnic group had a much higher tumour mutation burden (TMB) than the other ethnic groups. Typically, tumours from Han group had microsatellite stability, whereas those from the other groups had microsatellite instability (MSI). We further propose a molecular classification of four gastric cancer subtypes that are associated with distinct survival outcomes: TP53 mutation positive (TP53+)/TTN_missense+; TP53+/TTN_missense–; TP53–/TTN_missense+, and TP53–/TTN_missense–. Our study established a comprehensive gastric cancer genome atlas in China and underscored the importance of considering population context in genomic mapping and rational treatment options for the disease.
Citation Format: Liang Zong. Mutational landscape and genetic feature of gastric adenocarcinoma in multiple Chinese ethnicities [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2):Abstract nr B036.